These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38236916)

  • 1. An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.
    Abal M; Balouz V; Lopez R; Giorgi ME; Marino C; Cruz CV; Altcheh J; Buscaglia CA
    PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011910. PubMed ID: 38236916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study.
    Jurado Medina L; Chassaing E; Ballering G; Gonzalez N; Marqué L; Liehl P; Pottel H; de Boer J; Chatelain E; Zrein M; Altcheh J
    Lancet Infect Dis; 2021 Aug; 21(8):1141-1150. PubMed ID: 33836157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.
    Balouz V; Melli LJ; Volcovich R; Moscatelli G; Moroni S; González N; Ballering G; Bisio M; Ciocchini AE; Buscaglia CA; Altcheh J
    J Clin Microbiol; 2017 Dec; 55(12):3444-3453. PubMed ID: 28978686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal follow up of serological response in children treated for Chagas disease.
    Moscatelli G; Moroni S; García Bournissen F; González N; Ballering G; Schijman A; Corral R; Bisio M; Freilij H; Altcheh J
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007668. PubMed ID: 31465522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
    Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of α-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcomes of Chagas Disease.
    Ortega-Rodriguez U; Portillo S; Ashmus RA; Duran JA; Schocker NS; Iniguez E; Montoya AL; Zepeda BG; Olivas JJ; Karimi NH; Alonso-Padilla J; Izquierdo L; Pinazo MJ; de Noya BA; Noya O; Maldonado RA; Torrico F; Gascon J; Michael K; Almeida IC
    Methods Mol Biol; 2019; 1955():287-308. PubMed ID: 30868536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease.
    Montoya AL; Carvajal EG; Ortega-Rodriguez U; Estevao IL; Ashmus RA; Jankuru SR; Portillo S; Ellis CC; Knight CD; Alonso-Padilla J; Izquierdo L; Pinazo MJ; Gascon J; Suarez V; Watts DM; Malo IR; Ramsey JM; Alarcón De Noya B; Noya O; Almeida IC; Michael K
    Molecules; 2022 Sep; 27(17):. PubMed ID: 36080480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.
    Rivero R; Esteva MI; Huang E; Colmegna L; Altcheh J; Grossmann U; Ruiz AM;
    PLoS Negl Trop Dis; 2023 Jun; 17(6):e0011440. PubMed ID: 37352322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-like Particle Display of the α-Gal Epitope for the Diagnostic Assessment of Chagas Disease.
    Brito CR; McKay CS; Azevedo MA; Santos LC; Venuto AP; Nunes DF; D'Ávila DA; Rodrigues da Cunha GM; Almeida IC; Gazzinelli RT; Galvão LM; Chiari E; Sanhueza CA; Finn MG; Marques AF
    ACS Infect Dis; 2016 Dec; 2(12):917-922. PubMed ID: 27696820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease.
    Gazzinelli RT; Galvao LM; Krautz G; Lima PC; Cancado JR; Scharfstein J; Krettli AU
    Am J Trop Med Hyg; 1993 Nov; 49(5):625-35. PubMed ID: 8250103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of an enzyme-linked immunosorbent assay that utilizes the Tc13Tul antigen of Trypanosoma cruzi to monitor patients after treatment with benznidazole.
    Santamaría AL; De Rissio AM; Riarte A; Garavaglia PA; Bruballa AC; Rodríguez MA; Irazu LE; Ruiz AM; García GA
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):197-205. PubMed ID: 23537784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
    Altcheh J; Castro L; Dib JC; Grossmann U; Huang E; Moscatelli G; Pinto Rocha JJ; Ramírez TE;
    PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008912. PubMed ID: 33412557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of Galα(1,3)Galβ(1,4)GlcNAcα-, Galβ(1,4)GlcNAcα- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease.
    Schocker NS; Portillo S; Brito CR; Marques AF; Almeida IC; Michael K
    Glycobiology; 2016 Jan; 26(1):39-50. PubMed ID: 26384953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of a model trisaccharide for studying the interplay between the anti α-Gal antibody and the trans-sialidase reactions in Trypanosoma cruzi.
    Giorgi ME; Lopez R; Agusti R; Marino C; de Lederkremer RM
    Carbohydr Res; 2017 Oct; 450():30-37. PubMed ID: 28858610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.
    Rumi MM; Pérez Brandán C; Gil JF; D'Amato AM; Ragone PG; Lauthier JJ; Tomasini N; Cimino RO; Orellana V; Lacunza CD; Nasser JR; Basombrío MA; Diosque P
    Acta Trop; 2013 Oct; 128(1):130-6. PubMed ID: 23880286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Congenital Chagas disease: experience in the Hospital de Niños, Ricardo Gutiérrez, Buenos Aires, Argentina].
    Altcheh J; Biancardi M; Lapeña A; Ballering G; Freilij H
    Rev Soc Bras Med Trop; 2005; 38 Suppl 2():41-5. PubMed ID: 16482812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and characterization of α-d-Galp-(1 → 3)-β-d-Galp epitope-containing neoglycoconjugates for chagas disease serodiagnosis.
    Lopez R; Giorgi ME; Melgarejo LT; Ducrey I; Balouz V; González-Salas D; Cámara MLM; Buscaglia CA; de Lederkremer RM; Marino C
    Carbohydr Res; 2019 May; 478():58-67. PubMed ID: 31096122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of congenital Trypanosoma cruzi infection: A serologic test using Shed Acute Phase Antigen (SAPA) in mother-child binomial samples.
    Volta BJ; Russomando G; Bustos PL; Scollo K; De Rissio AM; Sánchez Z; Cardoni RL; Bua J
    Acta Trop; 2015 Jul; 147():31-7. PubMed ID: 25847262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lineage-specific rapid diagnostic tests can resolve Trypanosoma cruzi TcII/V/VI ecological and epidemiological associations in the Argentine Chaco.
    Murphy N; Macchiaverna NP; Victoria Cardinal M; Bhattacharyya T; Mertens P; Zeippen N; Gustin Y; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2019 Sep; 12(1):424. PubMed ID: 31522683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.